External innovation holds the key for long-term growth
03/12/20 -"Despite the generic erosion of Somatuline, Ipsen is targeting +2-5% sales growth p.a. until FY24, driven by the maximisation of the value of Cabometyx, Onivyde, Palovarotene, Decapeptyl and Dysport ..."
Pages
55
Language
English
Published on
03/12/20
You may also be interested by these reports :
01/07/25
Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...
26/06/25
Downside for 1H25E consensus – FY25E consensus should be fine – Mid-term potential reiterated
24/06/25
Just like Big Pharmas in aggregate, Sanofi’s (Buy; France) shares have gone nowhere over the last two years. After collapsing by c.19% in a day in ...
12/06/25
Only a month ago we were lamenting the weakness of Pharmas, the second larget sector by market cap. The tide may have turned, strangely as part ...